Pharmacotherapy for smoking cessation: Effects by subgroup defined by genetically informed biomarkers

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 9, 2017, Pages

  Schuit, Ewoud ^a,b   Panagiotou, Orestis A ^c   Munafò, Marcus R ^d   Bennett, Derrick A ^e   Bergen, Andrew W ^f   David, Sean P ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c BROWN UNIVERSITY   (United States)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f Biorealm   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; BIOLOGICAL MARKER; CYTOCHROME P450 2A6; NICOTINIC RECEPTOR; ORGANIC CATION TRANSPORTER 2; VARENICLINE; NICOTINE GUM;

COGNITIVE BEHAVIORAL THERAPY; DRUG EFFICACY; DRUG RESPONSE; FAGERSTROM TEST FOR NICOTINE DEPENDENCE; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMAN; METABOLIC PARAMETERS; NICOTINE METABOLITE RATIO; NICOTINE REPLACEMENT THERAPY; PHARMACOGENETIC TESTING; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING CESSATION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VARIABLE NUMBER OF TANDEM REPEAT; ADULT; DRUG THERAPY; GENETICS; META ANALYSIS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING; STATISTICS AND NUMERICAL DATA; TIME FACTOR;

ADULT; GENETIC MARKERS; GENOTYPE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMOKING; SMOKING CESSATION; TIME FACTORS; TOBACCO USE CESSATION PRODUCTS;

EID: 85028964943     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011823.pub2     Document Type: Review

References (249)

1. Ahluwalia JS, Okuyemi K, Nollen N, Choi WS, Kaur H, Pulvers K, et al. The effects of nicotine gum and counseling among African American light smokers: a 2 × 2 factorial design. Addiction 2006;101(6):883-91. 6669772
2. Ho MK, Mwenifumbo JC, Al Koudsi N, Okuyemi KS, Ahluwalia JS, Benowitz NL, et al. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clinical Pharmacology & Therapeutics 2009;85(6):635-43. 6669773
3. Zhu AZ, Zhou Q, Cox LS, David SP, Ahluwalia JS, Benowitz NL, et al. Association of CHRNA5-A3-B4 SNP rs2036527 with smoking cessation therapy response in African-American smokers. Clinical Pharmacology & Therapy 2014;96(2):256-65. 6669774
4. Aveyard P, Brown K, Saunders C, Alexander A, Johnstone E, Munafò MR, et al. Weekly versus basic smoking cessation support in primary care: a randomised controlled trial. Thorax 2007;62(10):898-903. [PUBMED: 17483139]6669776
5. David SP, Johnstone EC, Churchman M, Aveyard P, Murphy MF, Munafò MR. Pharmacogenetics of smoking cessation in general practice: results from the Patch II and Patch in Practice trials. Nicotine & Tobacco Research 2011;13(3):157-67. 6669777
6. David SP, Johnstone EC, Murphy MF, Aveyard P, Guo B, Lerman C, et al. Genetic variation in the serotonin pathway and smoking cessation with nicotine replacement therapy: new data from the Patch in Practice trial and pooled analyses. Drug and Alcohol Dependence 2008;98(1-2):77-85. 6669778
7. Munafò MR, Johnstone EC, Guo B, Murphy MF, Aveyard P. Association of COMT Val108/158Met genotype with smoking cessation. Pharmacogenetics and Genomics 2008;18(2):121-8. 6669779
8. Munafò MR, Johnstone EC, Murphy MF, Aveyard P. Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial. Nicotine & Tobacco Research 2009;11(4):404-7. 6669780
9. Munafò MR, Johnstone EC, Walther D, Uhl GR, Murphy MF, Aveyard P. CHRNA3 rs1051730 genotype and short-term smoking cessation. Nicotine & Tobacco Research 2011;13(10):982-8. 6669781
10. Spruell T, Colavita G, Donegan T, Egawhary M, Hurley M, Aveyard P, et al. Association between nicotinic acetylcholine receptor single nucleotide polymorphisms and smoking cessation. Nicotine & Tobacco Research 2012;14(8):993-7. 6669782
11. Uhl GR, Drgon T, Johnson C, Walther D, David SP, Aveyard P, et al. Genome-wide association for smoking cessation success: participants in the Patch in Practice trial of nicotine replacement. Pharmacogenomics 2010;11(3):357-67. 6669783
12. Bloch B, Reshef A, Cohen T, Tafla A, Gathas S, Israel S, et al. Preliminary effects of bupropion and the promoter region (HTTLPR) serotonin transporter (SLC6A4) polymorphism on smoking behavior in schizophrenia. Psychiatry Research 2010;175(1-2):38-42. 6669785
13. Brown RA, Niaura R, Lloyd-Richardson EE, Strong DR, Kahler CW, Abrantes AM, et al. Bupropion and cognitive-behavioral treatment for depression in smoking cessation. Nicotine & Tobacco Research 2007;9(7):721-30. 6669787
14. David SP, Brown RA, Papandonatos GD, Kahler CW, Lloyd-Richardson EE, Munafò MR, et al. Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine & Tobacco Research 2007;9(8):821-33. 6669788
15. David SP, Strong DR, Leventhal AM, Lancaster MA, McGeary JE, Munafò MR, et al. Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. Addiction 2013;108(12):2202-11. 6669789
16. David SP, Strong DR, Munafò MR, Brown RA, Lloyd-Richardson EE, Wileyto PE, et al. Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials. Nicotine & Tobacco Research 2007;9(12):1251-7. 6669790
17. Leventhal AM, David SP, Brightman M, Strong D, McGeary JE, Brown RA, et al. Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation. Pharmacogenomics Journal 2012;12(1):86-92. 6669791
18. Cinciripini P, Wetter D, Tomlinson G, Tsoh J, De Moor C, Cinciripini L, et al. The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood. Nicotine & Tobacco Research 2004;6(2):229-39. 6669793
19. Cinciripini PM, Tsoh JY, Wetter DW, Lam C, de Moor C, Cinciripini L, et al. Combined effects of venlafaxine, nicotine replacement, and brief counseling on smoking cessation. Experimenal & Clinical Psychopharmacology 2005;13(4):282-92. 6669794
20. Cox LS, Nollen NL, Mayo MS, Choi WS, Faseru B, Benowitz NL, et al. Bupropion for smoking cessation in African American light smokers: a randomized controlled trial. Journal of the National Cancer Institute 2012;104(4):290-8. 6669796
21. Zhu AZ, Cox LS, Nollen N, Faseru B, Okuyemi KS, Ahluwalia JS, et al. CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion. Clinical Pharmacology & Therapeutics 2012;92(6):771-7. 6669797
22. Zhu AZ, Zhou Q, Cox LS, Ahluwalia JS, Benowitz NL, Tyndale RF. Gene variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomes. Drug Metabolism & Disposition 2014;42(11):1971-7. 6669798
23. Zhu AZ, Zhou Q, Cox LS, David SP, Ahluwalia JS, Benowitz NL, et al. Association of CHRNA5-A3-B4 SNP rs2036527 with smoking cessation therapy response in African-American smokers. Clinical Pharmacology & Therapeutics 2014;96(2):256-65. 6669799
24. Gilbert DG, Zuo Y, Rabinovich NE, Riise H, Needham R, Huggenvik JI. Neurotransmission-related genetic polymorphisms, negative affectivity traits, and gender predict tobacco abstinence symptoms across 44 days with and without nicotine patch. Journal of Abnormal Psychology 2009;118(2):322-34. 6669801
25. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296(1):47-55. 6669803
26. King DP, Paciga S, Pickering E, Benowitz NL, Bierut LJ, Conti DV, et al. Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacology 2012;37(3):641-50. 6669804
27. David SP, Johnstone EC, Churchman M, Aveyard P, Murphy MF, Munafò MR. Pharmacogenetics of smoking cessation in general practice: results from the Patch II and Patch in Practice trials. Nicotine & Tobacco Research 2011;13(3):157-67. 6669806
28. David SP, Munafò MR, Murphy MF, Proctor M, Walton RT, Johnstone EC. Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch. Pharmacogenomics Journal 2008;8(2):122-8. 6669807
29. David SP, Munafò MR, Murphy MF, Walton RT, Johnstone EC. The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: follow-up of a randomized controlled trial. Nicotine & Tobacco Research 2007;9(2):225-31. 6669808
30. Imperial Cancer Research Fund General Practice Research Group. Effectiveness of a nicotine patch in helping people stop smoking: results of a randomised trial in general practice. BMJ 1993;306(6888):1304-8. 6669809
31. Johnstone EC, Elliot KM, David SP, Murphy MF, Walton RT, Munafò MR. Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiology Biomarkers & Prevention 2007;16(6):1065-9. 6669810
32. Johnstone EC, Yudkin PL, Hey K, Roberts SJ, Welch SJ, Murphy MF, et al. Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 2004;14(2):83-90. 6669811
33. Munafò MR, Elliot KM, Murphy MF, Walton RT, Johnstone EC. Association of the mu-opioid receptor gene with smoking cessation. Pharmacogenomics Journal 2007;7(5):353-61. 6669812
34. Munafò MR, Johnstone EC, Walther D, Uhl GR, Murphy MF, Aveyard P. CHRNA3 rs1051730 genotype and short-term smoking cessation. Nicotine & Tobacco Research 2011;13(10):982-8. 6669813
35. Bergen AW, Javitz HS, Krasnow R, Michel M, Nishita D, Conti DV, et al. Organic cation transporter variation and response to smoking cessation therapies. Nicotine & Tobacco Research 2014;16(12):1638-46. 6669815
36. Bergen AW, Javitz HS, Krasnow R, Nishita D, Michel M, Conti DV, e t al. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenetics and Genomics 2013;23(2):94-103. 6669816
37. Hall SM, Humfleet GL, Gorecki JA, Muñoz RF, Reus VI, Prochaska JJ. Older versus younger treatment-seeking smokers: differences in smoking behavior, drug and alcohol use, and psychosocial and physical functioning. Nicotine & Tobacco Research 2008;10(3):463-70. 6669817
38. Bergen AW, Javitz HS, Krasnow R, Michel M, Nishita D, Conti DV, et al. Organic cation transporter variation and response to smoking cessation therapies. Nicotine & Tobacco Research 2014;16(12):1638-46. 6669819
39. Bergen AW, Javitz HS, Krasnow R, Nishita D, Michel M, Conti DV, et al. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenetics and Genomics 2013;23(2):94-103. 6669820
40. Hall SM, Humfleet GL, Muñoz RF, Reus VI, Robbins JA, Prochaska JJ. Extended treatment of older cigarette smokers. Addiction 2009;104(6):1043-52. 6669821
41. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296(1):56-63. 6669823
42. King DP, Paciga S, Pickering E, Benowitz NL, Bierut LJ, Conti DV, et al. Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacology 2012;37(3):641-50. 6669824
43. Kalman D, Herz L, Monti P, Kahler CW, Mooney M, Rodrigues S, et al. Incremental efficacy of adding bupropion to the nicotine patch for smoking cessation in smokers with a recent history of alcohol dependence: results from a randomized, double-blind, placebo-controlled study. Drug and Alcohol Dependence 2011;118(2-3):111-8. 6669826
44. McGeary JE, Knopik VS, Hayes JE, Palmer RH, Monti PM, Kalman D. Predictors of relapse in a bupropion trial for smoking cessation in recently-abstinent alcoholics: preliminary results using an aggregate genetic risk score. Substance Abuse 2012;6:107-14. 6669827
45. Killen JD, Fortmann SP, Murphy GM Jr, Hayward C, Arredondo C, Cromp D, et al. Extended treatment with bupropion SR for cigarette smoking cessation. Journal of Consulting and Clinical Psychology 2006;74(2):286-94. 6669829
46. Sarginson JE, Killen JD, Lazzeroni LC, Fortmann SP, Ryan HS, Schatzberg AF, et al. Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy. American Journal of Medical Genetics B Neuropsychiatric Genetics 2011;156B(3):275-84. 6669830
47. Killen JD, Fortmann SP, Schatzberg AF, Arredondo C, Murphy G, Hayward C, et al. Extended cognitive behavior therapy for cigarette smoking cessation. Addiction 2008;103(8):1381-90. 6669832
48. Sarginson JE, Killen JD, Lazzeroni LC, Fortmann SP, Ryan HS, Schatzberg AF, et al. Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2011;156B(3):275-84. 6669833
49. Killen JD, Fortmann SP, Murphy GM Jr, Hayward C, Fong D, Lowenthal K, et al. Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy. Addiction 2010;105(9):1660-8. 6669835
50. Sarginson JE, Killen JD, Lazzeroni LC, Fortmann SP, Ryan HS, Ameli N, et al. Response to transdermal selegiline smoking cessation therapy and markers in the 15q24 chromosomal region. Nicotine & Tobacco Research 2015;17(9):1126-33. 6669836
51. Bergen AW, Javitz HS, Krasnow R, Michel M, Nishita D, Conti DV, et al. Organic cation transporter variation and response to smoking cessation therapies. Nicotine & Tobacco Research 2014;16(12):1638-46. 6669838
52. Bergen AW, Javitz HS, Krasnow R, Nishita D, Michel M, Conti DV, et al. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenetics and Genomics 2013;23(2):94-103. 6669839
53. Bergen AW, Javitz HS, Su L, He Y, Conti DV, Benowitz NL, et al. The DRD4 exon III VNTR, bupropion, and associations with prospective abstinence. Nicotine & Tobacco Research 2013;15(7):1190-200. 6669840
54. Berrettini WH, Wileyto EP, Epstein L, Restine S, Hawk L, Shields P, et al. Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. Biological Psychiatry 2007;61(1):111-8. 6669841
55. Conti DV, Lee W, Li D, Liu J, Van Den Berg D, Thomas PD, et al. Pharmacogenetics of Nicotine Addiction and Treatment Consortium. Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Human Molecular Genetics 2008;17(18):2834-48. 6669842
56. David SP, Strong DR, Leventhal AM, Lancaster MA, McGeary JE, Munafò MR, et al. Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. Addiction 2013;108(12):2202-11. 6669843
57. Gold AB, Wileyto EP, Lori A, Conti D, Cubells JF, Lerman C. Pharmacogenetic association of the galanin receptor (GALR1) SNP rs2717162 with smoking cessation. Neuropsychopharmacology 2012;37(7):1683-8. 6669844
58. Heitjan DF, Guo M, Ray R, Wileyto EP, Epstein LH, Lerman C. Identification of pharmacogenetic markers in smoking cessation therapy. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2008;147B(6):712-9. 6669845
59. Lee AM, Jepson C, Hoffmann E, Epstein L, Hawk LW, Lerman C, et al. CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Biological Psychiatry 2007;62(6):635-41. 6669846
60. Lee W, Bergen AW, Swan GE, Li D, Liu J, Thomas P, et al. Gender-stratified gene and gene-treatment interactions in smoking cessation. Pharmacogenomics Journal 2012;12(6):521-32. 6669847
61. Lee W, Ray R, Bergen AW, Swan GE, Thomas P, Tyndale RF, et al. DRD1 associations with smoking abstinence across slow and normal nicotine metabolizers. Pharmacogenetics and Genomics 2012;22(7):551-4. 6669848
62. Lerman C, Roth D, Kaufmann V, Audrain J, Hawk L, Liu A, et al. Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug and Alcohol Dependence 2002;67(2):219-23. 6669849
63. Lerman C, Shields PG, Wileyto EP, Audrain J, Hawk LH Jr, Pinto A, et al. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychology 2003;22(5):541-8. 6669850
64. Leventhal AM, Lee W, Bergen AW, Swan GE, Tyndale RF, Lerman C, et al. Nicotine dependence as a moderator of genetic influences on smoking cessation treatment outcome. Drug and Alcohol Dependence 2014;138:109-17. 6669851
65. Bergen AW, Javitz HS, Krasnow R, Nishita D, Michel M, Conti DV, et al. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenetics and Genomics 2013;23(2):94-103. 6669853
66. Gold AB, Wileyto EP, Lori A, Conti D, Cubells JF, Lerman C. Pharmacogenetic association of the galanin receptor (GALR1) SNP rs2717162 with smoking cessation. Neuropsychopharmacology 2012;37(7):1683-8. 6669854
67. Hutchison KE, Allen DL, Filbey FM, Jepson C, Lerman C, Benowitz NL, et al. CHRNA4 and tobacco dependence: from gene regulation to treatment outcome. Archives of General Psychiatry 2007;64(9):1078-86. 6669855
68. Lee AM, Jepson C, Shields PG, Benowitz N, Lerman C, Tyndale RF. CYP2B6 genotype does not alter nicotine metabolism, plasma levels, or abstinence with nicotine replacement therapy. Cancer Epidemiology Biomarkers & Prevention 2007;16(6):1312-4. 6669856
69. Lee W, Bergen AW, Swan GE, Li D, Liu J, Thomas P, et al. Gender-stratified gene and gene-treatment interactions in smoking cessation. Pharmacogenomics Journal 2012;12(6):521-32. 6669857
70. Lee W, Ray R, Bergen AW, Swan GE, Thomas P, Tyndale RF, et al. DRD1 associations with smoking abstinence across slow and normal nicotine metabolizers. Pharmacogenetics and Genomics 2012;22(7):551-4. 6669858
71. Lerman C, Kaufmann V, Rukstalis M, Patterson F, Perkins K, Audrain-McGovern J, et al. Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial. Annals of Internal Medicine 2004;140(6):426-33. 6669859
72. Lerman C, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, Restine S, et al. The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics Journal 2004;4(3):184-92. 6669860
73. Leventhal AM, Lee W, Bergen AW, Swan GE, Tyndale RF, Lerman C, et al. Nicotine dependence as a moderator of genetic influences on smoking cessation treatment outcome. Drug and Alcohol Dependence 2014;138:109-17. 6669861
74. Ray R, Jepson C, Wileyto EP, Dahl JP, Patterson F, Rukstalis M, et al. Genetic variation in mu-opioid-receptor-interacting proteins and smoking cessation in a nicotine replacement therapy trial. Nicotine & Tobacco Research 2007;9(11):1237-41. 6669862
75. Ray R, Mitra N, Baldwin D, Guo M, Patterson F, Heitjan DF, et al. Convergent evidence that choline acetyltransferase gene variation is associated with prospective smoking cessation and nicotine dependence. Neuropsychopharmacology 2010;35(6):1374-82. 6669863
76. Lerman C, Schnoll RA, Hawk LW Jr, Cinciripini P, George TP, Wileyto EP, et al. PGRN-PNAT Research Group. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. Lancet Respiratory Medicine 2015;3(2):131-8. 6669865
77. Tyndale RF, Zhu AZ, George TP, Cinciripini P, Hawk LW Jr, Schnoll RA, et al. PGRN-PNAT Research Group. Lack of associations of CHRNA5-A3-B4 genetic variants with smoking cessation treatment outcomes in Caucasian smokers despite associations with baseline smoking. PLoS One 2015;10(5):e0128109. 6669866
78. Marteau TM, Aveyard P, Munafò MR, Prevost AT, Hollands GJ, Armstrong D, et al. Effect on adherence to nicotine replacement therapy of informing smokers their dose is determined by their genotype: a randomised controlled trial. PLoS One 2014;7(4):e35249. 6669868
79. Munafò MR, Johnstone EC, Aveyard P, Marteau T. Lack of association of OPRM1 genotype and smoking cessation. Nicotine & Tobacco Research 2013;15(3):739-44. 6669869
80. Bergen AW, Javitz HS, Krasnow R, Michel M, Nishita D, Conti DV, et al. Organic cation transporter variation and response to smoking cessation therapies. Nicotine & Tobacco Research 2014;16(12):1638-46. 6669871
81. Bergen AW, Javitz HS, Krasnow R, Nishita D, Michel M, Conti DV, et al. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenetics and Genomics 2013;23(2):94-103. 6669872
82. McCarthy DE, Piasecki TM, Lawrence DL, Jorenby DE, Shiffman S, Fiore MC, et al. A randomized controlled clinical trial of bupropion SR and individual smoking cessation counseling. Nicotine & Tobacco Research 2008;10(4):717-29. 6669873
83. Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Archives of Internal Medicine 2006;166(15):151-7. 6669875
84. Bergen AW, Javitz HS, Krasnow R, Michel M, Nishita D, Conti DV, et al. Organic cation transporter variation and response to smoking cessation therapies. Nicotine & Tobacco Research 2014;16(12):1638-46. 6669877
85. Bergen AW, Javitz HS, Krasnow R, Nishita D, Michel M, Conti DV, et al. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenetics and Genomics 2013;23(2):94-103. 6669878
86. Piper ME, Federman EB, McCarthy DE, Bolt DM, Smith SS, Fiore MC, et al. Efficacy of bupropion alone and in combination with nicotine gum. Nicotine & Tobacco Research 2007;9(9):947-54. 6669879
87. Bergen AW, Javitz HS, Krasnow R, Michel M, Nishita D, Conti DV, et al. Organic cation transporter variation and response to smoking cessation therapies. Nicotine & Tobacco Research 2014;16(12):1638-46. 6669881
88. Bergen AW, Javitz HS, Krasnow R, Nishita D, Michel M, Conti DV, et al. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenetics and Genomics 2013;23(2):94-103. 6669882
89. Chen LS, Baker TB, Piper ME, Breslau N, Cannon DS, Doheny KF, et al. Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success. American Journal of Psychiatry 2012;169(7):735-42. 6669883
90. Chen LS, Bloom AJ, Baker TB, Smith SS, Piper ME, Martinez M, et al. Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6). Addiction 2014;109(1):128-37. 6669884
91. Piper ME, Smith SS, Schlam TR, Fiore MC, Jorenby DE, Fraser D, et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Archives of General Psychiatry 2009;66(11):1253-62. 6669885
92. Rose JE, Behm FM, Drgon T, Johnson C, Uhl GR. Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. Molecular Medicine 2010;16(7-8):247-53. 6669887
93. Gold AB, Wileyto EP, Lori A, Conti D, Cubells JF, Lerman C. Pharmacogenetic association of the galanin receptor (GALR1) SNP rs2717162 with smoking cessation. Neuropsychopharmacology 2012;37(7):1683-8. 6669889
94. Lerman C, Jepson C, Wileyto EP, Patterson F, Schnoll R, Mroziewicz M, et al. Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. Clinical Pharmacology & Therapeutics 2010;87(5):553-7. 6669890
95. Schnoll RA, Patterson F, Wileyto EP, Heitjan DF, Shields AE, Asch DA, et al. Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial. Annals of Internal Medicine 2010;152(3):144-51. 6669891
96. Sun H, Guo S, Chen D, Yang F, Zou Y, Di X, et al. Association of functional COMT Val108/Met polymorphism with smoking cessation in a nicotine replacement therapy. Journal of Neural Transmission (Vienna) 2012;119(12):1491-8. 6669893
97. Swan GE, Jack LM, Valdes AM, Ring HZ, Ton CC, Curry SJ, et al. Joint effect of dopaminergic genes on likelihood of smoking following treatment with bupropion SR. Health Psychology 2007;26(3):361-8. 6669895
98. Swan GE, McAfee T, Curry SJ, Jack LM, Javitz H, Dacey S, et al. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial. Archives of Internal Medicine 2003;163(19):2337-44. 6669896
99. Swan GE, Valdes AM, Ring HZ, Khroyan TV, Jack LM, Ton CC, et al. Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenomics Journal 2005;5(1):21-9. 6669897
100. Bergen AW, Javitz HS, Krasnow R, Michel M, Nishita D, Conti DV, et al. Organic cation transporter variation and response to smoking cessation therapies. Nicotine & Tobacco Research 2014;16(12):1638-46. 6669899
101. Bergen AW, Javitz HS, Krasnow R, Nishita D, Michel M, Conti DV, et al. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenetics and Genomics 2013;23(2):94-103. 6669900
102. Swan GE, McClure JB, Jack LM, Zbikowski SM, Javitz HS, Catz SL, et al. Behavioral counseling and varenicline treatment for smoking cessation. American Journal of Preventive Medicine 2010;38(5):482-90. 6669901
103. Verde Z, Santiago C, Rodríguez González-Moro JM, de Lucas Ramos P, López Martín S, Bandrés F, et al. Are serotonergic system genes associated to smoking cessation therapy success in addition to CYP2A6?. Pharmacopsychiatry 2014;47(1):33-6. [PUBMED: 24127329]6669903
104. Quaak M, van Schayck CP, Postma DS, Wagena EJ, van Schooten FJ. Genetic variants in the serotonin transporter influence the efficacy of bupropion and nortriptyline in smoking cessation. Addiction 2012;107(1):178-87. 6669905
105. Wagena EJ, Knipschild PG, Huibers MJ, Wouters EF, van Schayck CP. Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Archives of Internal Medicine 2005;165(19):2286-92. 6669906
106. Wilcox CS, Noble EP, Oskooilar N. ANKK1/DRD2 locus variants are associated with rimonabant efficacy in aiding smoking cessation: pilot data. Journal of Investigative Medicine 2011;59(8):1280-3. 6669908
107. De Ruyck K, Nackaerts K, Beels L, Werbrouck J, De Volder A, Meysman M, et al. Genetic variation in three candidate genes and nicotine dependence, withdrawal and smoking cessation in hospitalized patients. Pharmacogenomics 2010;11(8):1053-63. 6669910
108. Baker TB, Weiss RB, Bolt D, von Niederhausern A, Fiore MC, Dunn DM, et al. Human neuronal acetylcholine receptor A5-A3-B4 haplotypes are associated with multiple nicotine dependence phenotypes. Nicotine & Tobacco Research 2009;11(7):785-96. 6669912
109. Becker KM, Rose JE, Albino AP. A randomized trial of nicotine replacement therapy in combination with reduced-nicotine cigarettes for smoking cessation. Nicotine & Tobacco Research 2008;10(7):1139-48. 6669914
110. Uhl GR, Liu QR, Drgon T, Johnson C, Walther D, Rose JE. Molecular genetics of nicotine dependence and abstinence: whole genome association using 520, 000 SNPs. BMC Genetics 2007;8:10. 6669916
111. 1000 Genomes Project Consortium, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, et al. A global reference for human genetic variation. Nature 2015;526(7571):68-74. [PUBMED: 26432245]
112. Adkins DE, Souza RP, Aberg K, Clark SL, McClay JL, Sullivan PF, et al. Genotype-based ancestral background consistently predicts efficacy and side effects across treatments in CATIE and STAR*D. PLoS One 2013;8(2):e55239. [PUBMED: 23405125]
113. Agrawal A, Verweij KJ, Gillespie NA, Heath AC, Lessov-Schlaggar CN, Martin NG, et al. The genetics of addiction - a translational perspective. Translational Psychiatry 2012;2(e140):1-14. [PUBMED: 22806211]
114. Aguirre-Samudio AJ, Cruz-Fuentes CS, González-Sobrino BZ, Gutiérrez-Pérez V, Medrano-González L. Haplotype and nucleotide variation in the exon 3-VNTR of the DRD4 gene from indigenous and urban populations of Mexico. Am J Hum Biol 2014;26(5):682-9. [PUBMED: 24979719]
115. Attia J, Ioannidis JP, Thakkinstian A, McEvoy M, Scott RJ, Minelli C, et al. How to use an article about genetic association: A: background concepts. JAMA 2009;301(1):74-81. [PUBMED: 19126812]
116. Balfour DJ. The neuronal pathways mediating the behavioral and addictive properties of nicotine. Handbook of Experimental Pharmacology 2009;192:209-33. [PUBMED: 19184651]
117. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50(4):1088-101. [PUBMED: 7786990]
118. Bierut LJ, Stitzel JA, Wang JC, Hinrichs AL, Grucza RA, Xuei X, et al. Variants in nicotinic receptors and risk for nicotine dependence. American Journal of Psychiatry 2008;165(9):1163-71. [PUBMED: 18519524]
119. Benjamini Y, Bogomolov M. Selective inference on multiple families of hypotheses. Journal of the Royal Statistical Society Series B 2014;76(1):297-318.
120. Benowitz NL, Swan GE, Jacob P 3rd, Lessov-Schlaggar CN, Tyndale RF. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clinical Pharmacology and Therapeutics 2006;80(5):457-67. [PUBMED: 17112802]
121. Benowitz NL, Hukkanen J, Jacob P 3rd. Nicotine chemistry, metabolism, kinetics and biomarkers. Handbook of Experimental Pharmacology 2009;192:29-60. [PUBMED: 19184645]
122. Benowitz NL, Zhu AZ, Tyndale RF, Dempsey D, Jacob P 3rd. Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state. Pharmacogenetics and Genomics 2013;23(3):135-41. [PUBMED: 23344581]
123. Bergen AW, Javitz HS, Krasnow R, Nishita D, Michel M, Conti DV, et al. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenetics and Genomics 2013;23(2):94-103. [PUBMED: 23249876]
124. Bergen AW, Javitz HS, Krasnow R, Michel M, Nishita D, Conti DV, et al. Organic cation transporter variation and response to smoking cessation therapies. Nicotine & Tobacco Research 2014;16(12):1638-46. [PUBMED: 25143296]
125. Bidwell LC, Palmer RH, Brick L, McGeary JE, Knopik VS. Genome-wide single nucleotide polymorphism heritability of nicotine dependence as a multidimensional phenotype. Psychological Medicine 2016;46(10):2059-69. [PUBMED: 27052577]
126. Bloom AJ, Harari O, Martinez M, Madden PA, Martin NG, Montgomery GW, et al. Use of a predictive model derived from in vivo endophenotype measurements to demonstrate associations with a complex locus, CYP2A6. Human Molecular Genetics 2012;21(13):3050-62. [PUBMED: 22451501]
127. Bress A, Kittles R, Wing C, Hooker SE Jr, King A. Genetic ancestry as an effect modifier of naltrexone in smoking cessation among African Americans: an analysis of a randomized controlled trial. Pharmacogenetics and Genomics 2015;25(6):305-12. [PUBMED: 25918964]
128. Broms U, Silventoinen K, Madden PA, Heath AC, Kaprio J. Genetic architecture of smoking behavior: a study of Finnish adult twins. Twin Research and Human Genetics 2006;9(1):64-72. [PUBMED: 16611469]
129. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews 2012, Issue 4. [DOI: 10.1002/14651858.CD006103.pub6; PUBMED: 22513936]
130. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database of Systematic Reviews 2013;5:CD009329. [PUBMED: 23728690]
131. Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews 2016;9(5):CD006103.
132. Canova C, Hashibe M, Simonato L, Nelis M, Metspalu A, Lagiou P, et al. Genetic associations of 115 polymorphisms with cancers of the upper aerodigestive tract across 10 European countries: the ARCAGE project. Cancer Research 2009;69(7):2956-65. [PUBMED: 19339270]
133. Cardon LR, Idury RM, Harris TJ, Witte JS, Elston RC. Testing drug response in the presence of genetic information: sampling issues for clinical trials. Pharmacogenetics 2000;10(6):503-10. [PUBMED: 10975604]
134. Cardon LR, Palmer LJ. Population stratification and spurious allelic association. Lancet 2003;361(9357):598-604. [PUBMED: 12598158 ]
135. Carmelli D, Swan GE. Genetic influence on smoking - a study of male twins. New England Journal of Medicine 1992;327(12):829-33. [PUBMED: 1508241]
136. Chen LS, Baker TB, Piper ME, Breslau N, Cannon DS, Doheny KF, et al. Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success. American Journal of Psychiatry 2012;169(7):735-42. [PUBMED: 22648373]
137. Chen LS, Bloom AJ, Baker TB, Smith SS, Piper ME, Martinez M, et al. Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6). Addiction 2014;109(1):128-37. [PUBMED: 24033696]
138. Chen LS, Zawertailo L, Piasecki T, Kaprio J, Foreman M, Elliott H, et al. Genetics and Treatment Workgroup of the Society for Research on Nicotine and Tobacco (SRNT). Leveraging genomic data in smoking cessation trials in the era of Precision Medicine: why and how. Nicotine & Tobacco Research 2017 May 12;(manuscript in press). [PUBMED: 28498934]
139. Chenoweth MJ, Tyndale RF. Pharmacogenetic optimization of smoking cessation treatment. Trends in Pharmacological Science 2017;38(1):55-66. [PUBMED: 27712845]
140. David SP, Munafò MR, Murphy MF, Walton RT, Johnstone EC. The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: follow-up of a randomized controlled trial. Nicotine & Tobacco Research 2007;9(2):225-31.
141. David SP, Johnstone EC, Murphy MF, Aveyard P, Guo B, Lerman C, et al. Genetic variation in the serotonin pathway and smoking cessation with nicotine replacement therapy: new data from the Patch in Practice trial and pooled analyses. Drug and Alcohol Dependence 2008;98(1-2):77-85. [PUBMED: 18562131]
142. David SP, Munafò MR, Murphy MF, Proctor M, Walton RT, Johnstone EC. Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch. Pharmacogenomics Journal 2008;8(2):122-8.
143. David SP, Johnstone EC, Churchman M, Aveyard P, Murphy MF, Munafò MR. Pharmacogenetics of smoking cessation in general practice: results from the Patch II and Patch in Practice trials. Nicotine & Tobacco Research 2011;13(3):157-67. [PUBMED: 21330274]
144. David SP, Hamidovic A, Chen GK, Bergen AW, Wessel J, Kasberger JL, et al. Genome-wide meta-analyses of smoking behaviors in African Americans. Translational Psychiatry 2012;2:e119. [PUBMED: 22832964 ]
145. David SP, Strong DR, Leventhal AM, Lancaster MA, McGeary JE, Munafò MR, et al. Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. Addiction 2013;108(12):2202-11.
146. De Ruyck K, Nackaerts K, Beels L, Werbrouck J, De Volder A, Meysman M, et al. Genetic variation in three candidate genes and nicotine dependence, withdrawal and smoking cessation in hospitalized patients. Pharmacogenomics 2010;11(8):1053-63.
147. Debray TP, Moons KG, van Valkenhoef G, Efthimiou O, Hummel N, Groenwold RH, et al. GetReal Methods Review Group. Get real in individual participant data (IPD) meta-analysis: a review of the methodology. Research Synthesis Methods 2015;6:293-309. [PUBMED: 26287812]
148. Dempsey D, Tutka P, Jacob P 3rd, Allen F, Schoedel K, Tyndale RF, et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clinical Pharmacology & Therapeutics 2004;76(1):64-72. [PUBMED: 15229465]
149. Drgon T, Johnson C, Walther D, Albino AP, Rose JE, Uhl GR. Genome-wide association for smoking cessation success: participants in a trial with adjunctive denicotinized cigarettes. Molecular Medicine 2009;15(7-8):268-74. [PUBMED: 19593411]
150. Dudbridge F. Power and predictive accuracy of polygenic risk scores. PLoS Genetics 2013;9(3):e1003348. [PUBMED: 23555274]
151. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34. [PUBMED: 9310563]
152. Behrakis PK, Bilir N, Clancy L, Dautzenberg B, Demin AK, Gilljam H, et al. for the European Network for Smoking and Tobacco Prevention (ENSP). European Smoking Cessation Guidelines: The authoritative guide to a comprehensive understanding of the implications and implementation of treatments and strategies to treat tobacco dependence. http://ensp.org/wp-content/uploads/2016/12/ENSP-ESCG_FINAL.pdf 2012.
153. Fiore MC, Jaen CR, Baker TB. Clinical practice guideline - treating tobacco use and dependence: 2008 update. Rockville, MD: US Department of Health and Human Services, 2008; US Preventive Services Task Force. Behavioral and pharmacotherapy interventions for tobacco smoking cessation in adults, including pregnant women: recommendation statement. American Family Physician 2016;93:860A-G.
154. Fisher RA. Lung cancer and cigarettes?. Nature 1958;182(4628):108. [PUBMED: 13566198]
155. Fowler CD, Lu Q, Johnson PM, Marks MJ, Kenny PJ. Habenular α5 nicotinic receptor subunit signalling controls nicotine intake. Nature 2011;471(7340):597-601. [PUBMED: 21278726]
156. Freathy RM, Ring SM, Shields B, Galobardes B, Knight B, Weedon MN, et al. A common genetic variant in the 15q24 nicotinic acetylcholine receptor gene cluster (CHRNA5-CHRNA3-CHRNB4) is associated with a reduced ability of women to quit smoking in pregnancy. Human Molecular Genetics 2009;18(15):2922-7. [PUBMED: 19429911]
157. Freidlin B, Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clinical Cancer Research 2005;11(21):7872-8. [PUBMED: 16278411]
158. Freidlin B, Jiang W, Simon R. The cross-validated adaptive signature design. Clinical Cancer Research 2010;16(2):691-8. [PUBMED: 20068112]
159. Fujieda M, Yamazaki H, Saito T, Kiyotani K, Gyamfi MA, Sakurai M, et al. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis 2004;25(12):2451-8. [PUBMED: 15308589]
160. Gemignani F, Landi S, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, Rudnai P, et al. Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes. Carcinogenesis 2007;28(6):1287-93. [PUBMED: 17259654]
161. Giovino GA, Mirza SA, Samet JM, Gupta PC, Jarvis MJ, Bhala N, et al. GATS Collaborative Group. Tobacco use in 3 billion individuals from 16 countries: an analysis of nationally representative cross-sectional household surveys. Lancet 2012;380(9842):668-79. [PUBMED: 22901888]
162. Gold AB, Wileyto EP, Lori A, Conti D, Cubells JF, Lerman C. Pharmacogenetic association of the galanin receptor (GALR1) SNP rs2717162 with smoking cessation. Neuropsychopharmacology 2012;37(7):1683-8.
163. Hadjiconstantinou M, Neff NH. Nicotine and endogenous opioids: neurochemical and pharmacological evidence. Neuropharmacology 2011;60(7-8):1209-20. [PUBMED: 21108953]
164. Heath AC, Martin NG, Lynskey MT, Todorov AA, Madden PA. Estimating two-stage models for genetic influences on alcohol, tobacco or drug use initiation and dependence vulnerability in twin and family data. Twin Research 2002;5(2):113-24. [PUBMED: 11931689]
165. Herman AI, DeVito EE, Jensen KP, Sofuoglu M. Pharmacogenetics of nicotine addiction: role of dopamine. Pharmacogenomics 2014;15(2):221-34. [PUBMED: 24444411]
166. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
167. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
168. Ho MK, Mwenifumbo JC, Al Koudsi N, Okuyemi KS, Ahluwalia JS, Benowitz NL, et al. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clinical Pharmacology & Therapeutics 2009;85(6):635-43. [PUBMED: 19279561]
169. Hou L, Heilbronner U, Degenhardt F, Adli M, Akiyama K, Akula N, et al. Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet 2016;387(10023):1085-93. [PUBMED: 26806518]
170. Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T. Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD000031.pub4; PUBMED: 24402784]
171. Johnstone EC, Yudkin PL, Hey K, Roberts SJ, Welch SJ, Murphy MF, et al. Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 2004;14(2):83-90.
172. Johnstone E, Benowitz N, Cargill A, Jacob R, Hinks L, Day I, et al. Determinants of the rate of nicotine metabolism and effects on smoking behavior. Clinical Pharmacology & Therapeutics 2006;80(4):319-30. [PUBMED: 17015050]
173. Johnstone EC, Elliot KM, David SP, Murphy MF, Walton RT, Munafò MR. Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiology Biomarkers & Prevention 2007;16(6):1065-9.
174. King DP, Paciga S, Pickering E, Benowitz NL, Bierut LJ, Conti DV, et al. Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacology 2012;37(3):641-50. [PUBMED: 22048466]
175. Kotz D, Brown J, West R. Prospective cohort study of the effectiveness of smoking cessation treatments used in the "real world". Mayo Clinic Proceedings 2014;89(10):1360-7. [PUBMED: 25282429]
176. Landi MT, Chatterjee N, Yu K, Goldin LR, Goldstein AM, Rotunno M, et al. A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. American Journal of Human Genetics 2009;85(5):679-91. [PUBMED: 19836008]
177. Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, Pinto A, et al. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clinical Pharmacology & Therapeutics 2006;79(6):600-8. [PUBMED: 16765148]
178. Lerman C, Jepson C, Wileyto EP, Patterson F, Schnoll R, Mroziewicz M, et al. Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. Clinical Pharmacology and Therapeutics 2010;87(5):553-7. [PUBMED: 20336063]
179. Leung T, Bergen A, Munafò MR, De Ruyck K, Selby P, De Luca V. Effect of the rs1051730-rs16969968 variant and smoking cessation treatment: a meta-analysis. Pharmacogenomics 2015;16(7):713-20. [PUBMED: 25950378]
180. Leventhal AM, David SP, Brightman M, Strong D, McGeary JE, Brown RA, et al. Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation. Pharmacogenomics Journal 2012;12(1):86-92. [PUBMED: 20661272]
181. Leventhal AM, Lee W, Bergen AW, Swan GE, Tyndale RF, Lerman C, et al. Nicotine dependence as a moderator of genetic influences on smoking cessation treatment outcome. Drug and Alcohol Dependence 2014;1(138):109-17. [PUBMED: 24667010]
182. Li MD, Cheng R, Ma JZ, Swan GE. A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. Addiction 2003;98(1):23-31. [PUBMED: 12492752]
183. Liu JZ, Tozzi F, Waterworth DM, Pillai SG, Muglia P, Middleton L, et al. Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nature Genetics 2010;42(5):436-40. [PUBMED: 20418889]
184. Liu T, David SP, Tyndale RF, Wang H, Zhou Q, Ding P, et al. Associations of CYP2A6 genotype with smoking behaviors in southern China. Addiction 2011;106(5):985-94. [PUBMED: 21205058]
185. Mamoun M, Bergen AW, Shieh J, Wiggins A, Brody AL. Biomarkers of response to smoking cessation pharmacotherapies: progress to date. CNS Drugs 2015;29(5):359-69. [PUBMED: 25895022]
186. Matsui S, Buyse M, Simon R. Design and Analysis of Clinical Trials for Predictive Medicine. Boca Raton, FL: CRC Press, 2015.
187. McCaffery JM, Papandonatos GD, Lyons MJ, Koenen KC, Tsuang MT, Niaura R. Educational attainment, smoking initiation and lifetime nicotine dependence among male Vietnam-era twins. Psychological Medicine 2008;38(9):1287-97. [PUBMED: 17949517]
188. McClay JL, Adkins DE, Aberg K, Stroup S, Perkins DO, Vladimirov VI, et al. Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Molecular Psychiatry 2011;16(1):76-85. [PUBMED: 19721433]
189. McClure JB, Swan GE, St John J, Fauver R, Javitz HS, Bergen AW, et al. Pharmacogenetic smoking cessation intervention in a health care setting: a pilot feasibility study. Nicotine & Tobacco Research 2013;15(2):518-26. [PUBMED: 22949583]
190. McDonagh EM, Wassenaar C, David SP, Tyndale RF, Altman RB, Whirl-Carrillo M, et al. PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6. Pharmacogenetics and Genomics 2012;22(9):695-708. [PUBMED: 22547082]
191. McGeary JE, Knopik VS, Hayes JE, Palmer RH, Monti PM, Kalman D. Predictors of relapse in a bupropion trial for smoking cessation in recently-abstinent alcoholics: preliminary results using an aggregate genetic risk score. Substance Abuse 2012;6:107-14.
192. McKay JD, Hung RJ, Gaborieau V, Boffetta P, Chabrier A, Byrnes G, et al. Lung cancer susceptibility locus at 5p15.33. Nature Genetics 2008;40(12):1404-6. [PUBMED: 18978790]
193. Mills EJ, Wu P, Lockhart I, Thorlund K, Puhan M, Ebbert JO. Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis. Annals of Medicine 2012;44(6):588-97. [PUBMED: 22860882]
194. Munafò MR, Elliot KM, Murphy MF, Walton RT, Johnstone EC. Association of the mu-opioid receptor gene with smoking cessation [Association of the mu-opioid receptor gene with smoking cessation]. Pharmacogenomics Journal 2007 ;7(5):353-61. [17224915]
195. Munafò MR, Johnstone EC, Guo B, Murphy MF, Aveyard P. Association of COMT Val108/158Met genotype with smoking cessation. Pharmacogenetics and Genomics 2008;18(2):121-8. [PUBMED: 18192898]
196. Munafò MR, Johnstone EC, Murphy MF, Aveyard P. Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial. Nicotine & Tobacco Research 2009;11(4):404-7. [PUBMED: 19273465]
197. Munafò MR, Johnstone EC, Walther D, Uhl GR, Murphy MF, Aveyard P. CHRNA3 rs1051730 genotype and short-term smoking cessation. Nicotine & Tobacco Research 2011;13(10):982-8. [PUBMED: 21690317]
198. Munafò MR, Timofeeva MN, Morris RW, Prieto-Merino D, Sattar N, Brennan P, et al. EPIC Study Group, Davey Smith G. Association between genetic variants on chromosome 15q25 locus and objective measures of tobacco exposure. Journal of the National Cancer Institute 2012;104(10):740-8. [PUBMED: 22534784]
199. Munafò MR, Johnstone EC, Aveyard P, Marteau T. Lack of association of OPRM1 genotype and smoking cessation. Nicotine & Tobacco Research 2013;15(3):739-44.
200. Murphy E, Hou L, Maher BS, Woldehawariat G, Kassem L, Akula N, et al. Race, genetic ancestry and response to antidepressant treatment for major depression. Neuropsychopharmacology 2013;38(13):2598-606. [PUBMED: 23827886]
201. Murphy SE, Park SS, Thompson EF, Wilkens LR, Patel Y, Stram DO, et al. Nicotine N-glucuronidation relative to N-oxidation and C-oxidation and UGT2B10 genotype in five ethnic/racial groups. Carcinogenesis 2014;35(11):2526-33. [PUBMED: 25233931]
202. Patnode CD, Henderson JT, Thompson JH, Senger CA, Fortmann SP, Whitlock EP. Behavioral Counseling and Pharmacotherapy Interventions for Tobacco Cessation in Adults, Including Pregnant Women: A Review of Reviews for the US Preventive Services Task Force. Rockville (MD): Agency for Healthcare Research and Quality (US) 2015 Sep; Vol. Report No.: 14-05200-EF-1. [PUBMED: 26491759]
203. Patterson F, Schnoll RA, Wileyto EP, Pinto A, Epstein LH, Shields PG, et al. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clinical Pharmacology & Therapeutics 2008;84(3):320-5. [PUBMED: 18388868]
204. Pearson TA, Manolio TA. How to interpret a genome-wide association study. JAMA 2008;299(11):1335-44. [PUBMED: 18349094]
205. Peralta-Leal V, Leal-Ugarte E, Meza-Espinoza JP, Dávalos-Rodríguez IP, Bocanegra-Alonso A, Acosta-González RI, Gonzales E, Nair S, Durán-González J. Association of a serotonin transporter gene (SLC6A4) 5-HTTLPR polymorphism with body mass index categories but not type 2 diabetes mellitus in Mexicans. Genet Mol Biol 2012;35(3):589-93. [PUBMED: 23055796]
206. Quaak M, Van Schayck CP, Postma DS, Wagena EJ, Van Schooten FJ. Genetic variants in the serotonin transporter influence the efficacy of bupropion and nortriptyline in smoking cessation. Addiction 2012;107(1):178-87. [PUBMED: 21658141]
207. Ray R, Jepson C, Wileyto EP, Dahl JP, Patterson F, Rukstalis M, et al. Genetic variation in mu-opioid-receptor-interacting proteins and smoking cessation in a nicotine replacement therapy trial. Nicotine & Tobacco Research 2007;9(11):1237-41. [PUBMED: 17978999]
208. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
209. Rotunno M, Yu K, Lubin JH, Consonni D, Pesatori AC, Goldstein AM, et al. Phase I metabolic genes and risk of lung cancer: multiple polymorphisms and mRNA expression. PLoS One 2009;4(5):e5652. [PUBMED: 19479063]
210. Saccone NL, Culverhouse RC, Schwantes-An TH, Cannon DS, Chen X, Cichon S, et al. Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. PLoS Genetics 2010;6(8):e1001053. [PUBMED: 20700436]
211. Saccone N, Baurley JW, Bergen AW, David SP, Elliott H, Foreman M, et al. Genetics and Treatment Networks of the Society for Research on Nicotine and Tobacco (SRNT). The value of biosamples in smoking cessation trials: a review of genetic, metabolomic, and epigenetic findings. Nicotine & Tobacco Research 2017 May 3;(manuscript in press). [PUBMED: 28472521]
212. Sarginson JE, Killen JD, Lazzeroni LC, Fortmann SP, Ryan HS, Schatzberg AF, et al. Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2011;156B(3):275-84.
213. Sarginson JE, Killen JD, Lazzeroni LC, Fortmann SP, Ryan HS, Ameli N, et al. Response to transdermal selegiline smoking cessation therapy and markers in the 15q24 chromosomal region. Nicotine & Tobacco Research 2015;17(9):1126-33.
214. Scherf DB, Sarkisyan N, Jacobsson H, Claus R, Bermejo JL, Peil B, et al. Epigenetic screen identifies genotype-specific promoter DNA methylation and oncogenic potential of CHRNB4. Oncogene 2012;32(28):3329-38. [PUBMED: 22945651]
215. Schnoll RA, Patterson F, Wileyto EP, Tyndale RF, Benowitz N, Lerman C. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacology, Biochemistry, and Behavior 2009;92(1):6-11. [PUBMED: 19000709]
216. Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult caucasians. Pharmacogenetics 2004;14(9):615-26. [PUBMED: 15475735]
217. Spruell T, Colavita G, Donegan T, Egawhary M, Hurley M, Aveyard P, et al. Association between nicotinic acetylcholine receptor single nucleotide polymorphisms and smoking cessation. Nicotine & Tobacco Research 2012;14(8):993-7. [PUBMED: 22180580]
218. Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/14651858.CD000146.pub4; PUBMED: 23152200]
219. Stead LF, Lancaster T. Behavioural interventions as adjuncts to pharmacotherapy for smoking cessation. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD009670.pub2; PUBMED: 23235680]
220. Sullivan PF, Neale BM, Van den Oord E, Miles MF, Neale MC, Bulik CM, et al. Candidate genes for nicotine dependence via linkage, epistasis, and bioinformatics. American Journal of Medical Genetics: Part B Neuropsychiatric Genetics 2004;126B(1):23-36. [PUBMED: 15048644]
221. Sun J, Kranzler HR, Bi J. An effective method to identify heritable components from multivariate phenotypes. PLoS One 2015;10(12):e0144418. [PUBMED: 26658140]
222. Swan GE, Valdes AM, Ring HZ, Khroyan TV, Jack LM, Ton CC, et al. Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenomics Journal 2005;5(1):21-9.
223. Swan GE, Jack LM, Valdes AM, Ring HZ, Ton CC, Curry SJ, et al. Joint effect of dopaminergic genes on likelihood of smoking following treatment with bupropion SR. Health Psychology 2007;26(3):361-8.
224. Tamaki Y, Arai T, Sugimura H, Sasaki T, Honda M, Muroi Y, et al. Association between cancer risk and drug-metabolizing enzyme gene (CYP2A6, CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1) polymorphisms in cases of lung cancer in Japan. Drug Metabolism and Pharmacokinetics 2011;26(5):516-22. [PUBMED: 21791872]
225. Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008;452(7187):638-42. [PUBMED: 18385739]
226. Thorgeirsson TE, Gudbjartsson DF, Surakka I, Vink JM, Amin N, Geller F, et al. Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nature Genetics 2010;42(5):448-53. [PUBMED: 20418888]
227. Tierney JF, Vale C, Riley R, Smith CT, Stewart L, Clarke M, et al. Individual participant data (IPD) meta-analyses of randomised controlled trials: guidance on their use. PLoS Medicine 2015;12:e1001855. [PUBMED: 26196287]
228. Tobacco and Genetics Consortium. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nature Genetics 2010;42(5):441-7. [PUBMED: 20418890]
229. Topcu Z, Chiba I, Fujieda M, Shibata T, Ariyoshi N, Yamazaki H, et al. CYP2A6 gene deletion reduces oral cancer risk in betel quid chewers in Sri Lanka. Carcinogenesis 2002;23(4):595-8. [PUBMED: 11960911]
230. Trinidad DR, Xie B, Fagan P, Pulvers K, Romero DR, Blanco L, et al. Disparities in the population distribution of African American and non-Hispanic white smokers along the quitting continuum. Health Education & Behavior 2015;42(6):742-51. [PUBMED: 25794519]
231. True WR, Heath AC, Scherrer JF, Waterman B, Goldberg J, Lin N, et al. Genetic and environmental contributions to smoking. Addiction 1997;92(10):1277-87. [PUBMED: 9489045]
232. Tyndale RF, Zhu AZ, George TP, Cinciripini P, Hawk LW Jr, Schnoll RA, et al. PGRN-PNAT Research Group. Lack of associations of CHRNA5-A3-B4 genetic variants with smoking cessation treatment outcomes in Caucasian smokers despite associations with baseline smoking. PLoS One 2015;10(5):e0128109. [PUBMED: 26010901]
233. Uhl GR, Liu QR, Drgon T, Johnson C, Walther D, Rose JE, et al. Molecular genetics of successful smoking cessation: convergent genome-wide association study results. Archives of General Psychiatry 2008;65(6):683-93. [PUBMED: 18519826]
234. Uhl GR, Drgon T, Johnson C, Walther D, David SP, Aveyard P, et al. Genome-wide association for smoking cessation success: participants in the Patch in Practice trial of nicotine replacement. Pharmacogenomics 2011;11(3):357-67. [PUBMED: 20235792]
235. Uhl GR, Walther D, Musci R, Fisher C, Anthony JC, Storr CL, et al. Smoking quit success genotype score predicts quit success and distinct patterns of developmental involvement with common addictive substances. Molecular Psychiatry 2014;19(1):50-4. [PUBMED: 23128154]
236. Varadhan R, Segal JB, Boyd CM, Wu AW, Weiss CO. A framework for the analysis of heterogeneity of treatment effect in patient-centered outcomes research. Journal of Clinical Epidemiology 2013;66(8):818-25. [PUBMED: 23651763]
237. Verhagen M, Kleinjan M, Engels RC. A systematic review of the A118G (Asn40Asp) variant of OPRM1 in relation to smoking initiation, nicotine dependence and smoking cessation. Pharmacogenomics 2013;13(8):917-33. [PUBMED: 22676196]
238. Wang J, Li MD. Common and unique biological pathways associated with smoking initiation/progression, nicotine dependence, and smoking cessation. Neuropsychopharmacology 2010;35(3):702-19. [PUBMED: 19890259]
239. Wang JC, Spiegel N, Bertelsen S, Le N, McKenna N, Budde JP, e t al. Cis-regulatory variants affect CHRNA5 mRNA expression in populations of African and European ancestry. PLoS One 2013;8(11):e80204. [PUBMED: 24303001]
240. Ware JJ, Van den Bree M, Munafò MR. From men to mice: CHRNA5/CHRNA3, smoking behavior and disease. Nicotine & Tobacco Research 2012;14(11):1291-9. [PUBMED: 22544838]
241. Weiss ST. Implementing personalized medicine in the academic health center. Journal of Personalize Medicine 2016;6(3):E18. [PUBMED: 27657137]
242. West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax 2000;55(12):987-99. [PUBMED: 11083883]
243. Xian H, Scherrer JF, Grant JD, Eisen SA, True WR, Jacob T, et al. Genetic and environmental contributions to nicotine, alcohol and cannabis dependence in male twins. Addiction 2008;103(8):1391-8. [PUBMED: 18855830]
244. Yudkin P, Munafò M, Hey K, Roberts S, Welch S, Johnstone E, et al. Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial. BMJ 2004;328(7446):989-90. [PUBMED: 15033882]
245. Zanetti KA, Wang Z, Aldrich M, Amos CI, Blot WJ, Bowman ED, et al. Genome-wide association study confirms lung cancer susceptibility loci on chromosomes 5p15 and 15q25 in an African-American population. Lung Cancer 2016;98:33-42. [PUBMED: 27393504]
246. Zhu AZ, Cox LS, Nollen N, Faseru B, Okuyemi KS, Ahluwalia JS, et al. CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion. Clinical Pharmacology & Therapeutics 2012;92(6):771-7. [PUBMED: 23149928]
247. Zhu AZ, Zhou Q, Cox LS, Ahluwalia JS, Benowitz NL, Tyndale RF. Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake. PLoS One 2013;8(8):e70938. [PUBMED: 23936477]
248. Zhu AZ, Zhou Q, Cox LS, David SP, Ahluwalia JS, Benowitz NL, et al. Association of CHRNA5-A3-B4 SNP rs2036527 with smoking cessation therapy response in African American smokers. Clinical Pharmacology & Therapeutics 2014;96(2):256-65. [PUBMED: 24733007]
249. Sean P David, Andrew W Bergen, Marcus R Munafò, Ewoud Schuit, Derrick A Bennett, Orestis A. Panagiotou. Genomic analysis to guide choice of treatment for smoking cessation. Cochrane Database of Systematic Reviews 3 August 2015. [DOI: 10.1002/14651858.CD011823]